[ad_1]
The Mexican government is studying the case of a doctor who is in intensive care for developing encephalitis, inflammation in the brain, after receiving the vaccine from Pfizer and BioNTech against COVID-19
.
“With the scientific evidence available from clinical trials of the Pfizer-BioNTech BNT162b2 vaccine against the SARS-CoV-2 virus, no person had previously developed encephalitis after the application of the vaccine“, informed the Ministry of Health (SSa) in a statement.
The government agency specified that the woman is a 32-year-old doctor from the Mexican Institute of Social Security (IMSS) in the northern state of Nuevo León, where she received the drug this week.
The doctor, said the SSa, has a history of allergic reactions to drugs such as trimethoprim with sulfamethoxazole, an antibiotic that fights urinary infections.
Its initial diagnosis is encephalomyelitis, which is described as a brief but intense attack of inflammation in the brain, usually from a viral infection.
The woman developed a skin rash, seizures, decreased muscle strength, and respiratory distress within half an hour after dosing.
“The reaction was detected within the specific observation area of the vaccination cell in which the doctor received her vaccine”, indicated the SSa.
Mexico
It is one of the first countries in the world to initiate vaccination against COVID-19, but so far it has only received about 53,000 doses of the drug from Pfizer-BioNTech, all applied to healthcare personnel.
The Government of Mexico, where the pandemic has left more than 1.4 million infections and more than 126,000 deaths, has opted for early access to the vaccine.
The country has pre-purchase contracts for 34.4 million doses of Pfizer
, 77.4 million from the British AstraZeneca, 35 million from the Chinese CanSino and 34.4 million from the Covax platform of the World Health Organization (WHO).
Mexican President Andrés Manuel López Obrador promised that will vaccinate against COVID-19
to all health personnel by the end of January and to “most” of its vulnerable population by April.
Mexico will receive another batch of Pfizer vaccines this Tuesday, in addition to the fact that next week the acquisition of 12 million doses for three months, from January to March, from the Chinese company CanSino will be formalized.
Meanwhile, the Ministry of Health (SSa) affirmed that it follows the protocol of “Events supposedly attributable to vaccination and immunization” of the Federal Commission for Protection against Sanitary Risks (Cofepris).
“The doctor is under observation and treatment by specialists in critical medicine to reduce the brain inflammation presented. Intensive specialized treatment will continue”, he concluded.
Meanwhile, in Argentina, 317 people have presented adverse effects to the Russian vaccine, such as fever and headache.
[ad_2]
